Document Classification

Section Type: METHODS

Text: Chemotherapy-nave patients with measurable unresectable and/or metastatic gastric carcinoma, a performance status < or = 1, and adequate hematologic, hepatic, and renal function randomly received < or = eight 3-weekly cycles of ECF (epirubicin 50 mg/m (2) on day 1, cisplatin 60 mg/m (2) on day 1, and fluorouracil [FU] 200 mg/m (2) / d on days 1 to 21), TC (docetaxel initially 85 mg/m (2) on day 1 [later reduced to 75 mg/m (2) as a result of toxicity] and cisplatin 75 mg/m (2) on day 1), or TCF (TC plus FU 300 mg/m (2) / d on days 1 to 14).